91494-44-9

Basic information

• Product Name: 1-(3-chloropropanoyl)-1,2,3,4-tetrahydroquinoline
• Synonyms: 1-(3-chloropropanoyl)-1,2,3,4-tetrahydroquinoline;UKRORGSYN-BB BBV-019075;1-(3-chloropropanoyl)-1,2,3,4-tetrahydroquinoline(SALTDATA: FREE)
• CAS NO: 91494-44-9
• Molecular Formula: C₁₂H₁₄ClNO
• Molecular Weight: 223.7
• Mol File: 91494-44-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 421.6°C at 760 mmHg
• Flash Point: 208.8°C
• Appearance: /
• Density: 1.199g/cm³
• Vapor Pressure: 2.58E-07mmHg at 25°C
• Refractive Index: 1.564
• CAS DataBase Reference: 1-(3-chloropropanoyl)-1,2,3,4-tetrahydroquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-chloropropanoyl)-1,2,3,4-tetrahydroquinoline(91494-44-9)
• EPA Substance Registry System: 1-(3-chloropropanoyl)-1,2,3,4-tetrahydroquinoline(91494-44-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 91494-44-9(Hazardous Substances Data)

Usage

General Description

1-(3-chloropropanoyl)-1,2,3,4-tetrahydroquinoline is a chemical compound with the molecular formula C13H15ClNO. It is a tetrahydroquinoline derivative that contains a 3-chloropropanoyl group, which is often used in the synthesis of pharmaceuticals and other organic compounds. 1-(3-chloropropanoyl)-1,2,3,4-tetrahydroquinoline has potential applications in the development of new drugs and has been studied for its biological activity. The 3-chloropropanoyl group contributes to the compound's properties and reactivity, making it useful for various chemical reactions and processes. Overall, 1-(3-chloropropanoyl)-1,2,3,4-tetrahydroquinoline is a versatile and important chemical compound with potential applications in the pharmaceutical and chemical industries.

InChI:InChI=1/C12H14ClNO/c13-8-7-12(15)14-9-3-5-10-4-1-2-6-11(10)14/h1-2,4,6H,3,5,7-9H2

Upstream product

• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 625-36-5 2-chloropropionyl chloride 

Downstream Products

• 1616622-79-7 9-(5-(2-(4-methylbenzenesulfonyl)oxyethyloxy)pyridin-3-yl)-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one 

Relevant articles and documents

Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics

Herein, a novel series of multireceptor ligands was developed as polypharmacological antipsychotic agents using the designed multiple ligand approach between dopamine receptors and serotonin receptors. Among them, compound 47 possessed unique pharmacological features, exhibiting high affinities for D2, D3, 5-HT1A, 5-HT2A, and 5-HT6 receptors and low efficacy at the off-target receptors (5-HT2C, histamine H1, and adrenergic α1 receptor). Compound 47 showed dose-dependent inhibition of apomorphine- and MK-801-induced motor behavior, and the conditioned avoidance response with low cataleptic effect. Moreover, compound 47 resulted nonsignificantly serum prolactin levels and weight gain change compared with risperidone. Additionally, compound 47 possessed a favorable pharmacokinetic profile with oral bioavailability of 58.8% in rats. Furthermore, compound 47 displayed procognition properties in a novel object recognition task in rats. Taken together, compound 47 may constitute a novel class of atypical antipsychotic drugs for schizophrenia.

RADIOACTIVE QUINOLINONE DERIVATIVE AND PHARMACEUTICAL DRUG COMPRISING THE SAME

It is intended to provide a radioactive compound that has higher selectivity for CYP11B2 than that for CYP11B1, exhibits highly selective accumulation in the adrenal gland compared with blood and organs adjacent to the adrenal gland, and permits commercial supply. The present invention provides a radioactive quinolinone derivative represented by the predetermined general formula or a salt thereof.

6-PYRIDIN-3-YL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN ALDOSTERONE SYNTHASE CYP11B2

The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and/or disorders or diseases that are mediated by 11 β-hydroxylase (CYP11 B1 ).